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INTRODUCTION 
 
 
The extensive clinical spectrum of gastro intestinal bleeding may encompass many 
different scenario. 
 
The reason for this diversity is bleeding can occur from multiple different lesions 
and many sites in the gastro intestinal tract. 
 
Gastro intestinal bleeding is a common clinical problem requiring more than 
300,000 hospitalization annuals. 
 
 Upper Gastrointestinal bleeding, which most commonly arises from mucosal 
erosive diseases, account for upto 20,000 deaths annually. 
  
The overall incidence of acute upper gastrointestinal hemorrhage has been 
estimated to be 50-100 per 1,00,000 person per year, with an annual 
hospitalization rate of approximately 100 per 1, 00,000 hospital admission. 
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Bleeding from upper gastrointestinal tract is approximately five times more 
common than bleeding from lower gastrointestinal tract. Bleeding may be massive 
or trivial, obvious or hidden.Gastrointestinal bleeding occurs clinically in one or 
more of the following four ways 1. Hemet emesis (from the Upper IT) 2. 
Hematochezia (from the lower GIT) 3. Occult (unknown to the patient) 4. Obscure 
(from an unknown site in the GIT). 
 
The most important in the management of gastrointestinal bleeding is to determine 
1. Source of bleeding 2. Stop active bleeding 3. Treat underlying abnormality 4. 
Prevent recurrent bleeding. 
 
Historically, the most common cause of upper GI bleeding has been gastro 
duodenal ulcer disease, although other upper gastro intestinal tract mucosal lesion 
account for a substantial proportion of cases. 
 
 
 
 
 
 
.    
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AIM OF THE STUDY 
 
 
1. To find out the prevalence of nature of lesion on Upper Gastro Endoscopy 
in patients admitted for UGI bleed. 
 
2. To find out the prevalence of nature of lesion in patients with minor, 
moderate, major bleed. 
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REVIEW OF LITERATURE 
 
UPPER GASTRO INTESTINAL BLEED 
 
3.1 DEFINITION: 1 
 
Vomiting of blood almost always proximal to the ligament of Treitz. 
 
Manifestations: 
 
Hemetemesis : Vomiting of blood, may be fresh and bright red color or old, 
 
                          with the appearance of coffee grounds. 
 
Melena :           Passage of black, tarry, and  foul-smelling stool results from 
   
                         degradation of blood to hematin or other hemochromes by 
 
                          bacteria. 
 
3.2 Symptoms : 
 
Hemetemesis and Melena 
 
Postural giddiness 
 
Palpitation 
 
Sweating 
 
Signs: 
  
BP:  Resting hypotension and postural hypotension and tachycardia  
 
Signs of liver disease:   Jaundice,spider angiomata, palmar  
erythema,dupytren’s contracture. 
Signs of portal hypertension: Spleenomegaly , ascites and caput medusae 
Acanthosis nigricans (underlying malignancy) 
 
 
Cutaneous telengiectasias of skin, mucous membranes.     
Abdominal mass and tenderness. 
 
 5
 
 
3.3 Historical Features That Help Assess the Etiology of Gastrointestinal Bleeding1 
 
 
• Age  
• Prior gastrointestinal bleeding  
• Previous gastrointestinal disease  
• Previous gastrointestinal surgery   
• Underlying medical disorder (especially liver disease) 
• Use of nonsteroidal anti – inflammatory drugs, including aspirin 
• Use of anticoagulation and / or anti – platelet therapy 
• Abdominal pain 
• Change in bowel habits 
• Weight loss 
• Anorexia  
• History of orophyrangeal disease. 
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3.5 ADVERSE PROGNOSTIC VARIABLE IN PATIENTS WITH ACUTE 
UPPER GASTROINTESTINAL BLEEDING2,3 
 
 
Increasing age 
 
¾ Increasing number of comorbid conditions (especially renal failure, liver 
failure, heart failure, cardiovascular disease, disseminated malignancy). 
 
¾ Variceal bleeding (as compared with non variceal bleeding)  
¾ Shock or hypotension on presentation 
¾ Red blood in the emesis or stool 
¾ Increasing number of units of blood transfused  
¾ Active bleeding at the time of endoscopy 
¾ Bleeding from a large (> 2.0cm) ulcer 
¾ Bleeding from a visible or spurting vessel  
¾ Onset of bleeding in the hospital  
¾ Need for emergency surgery. 
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3.6  CAUSES OF ACUTE UPPER GASTROINTESTINAL BLEEDING1 
Common  
• Gastric ulcer 
• Duodenal ulcer 
• Esophageal varices 
• Mallory – Weiss tear 
Less Common 
• Gastric erosions / gastropathy  
• Esophagitis 
• Cameron lesions / Dieulafoy lesion 
• Telangiectasias  
• Portal hypertensive gastropathy / gastric varices 
• Gastric antral vascular ectasia (watermelon stomach) 
• Neoplasm 
Rare  
• Esophageal ulcer 
• Erosive duodenitis 
• Hemobilia  
• Pancreatic disease / crohn’s disease 
• Aortoenteric fistula 
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3.6 CAUSES: 
3.6.1 Esophagitis1: 
Common cause of upper gastrointestinal bleeding, occurring in nearly 15% of 
patients who undergo endoscopy bleeding. 
Severe bleeding is less frequent. It causes occult blood loss more commonly than 
it causes acute bleeding 
Obvious bleeding is most likely in patients with extensive erosive disease. 
3.6.2 Mallory-Weiss Tear4: 
Lacerations in the region of gastro esophageal junction that typically occur in the 
gastric mucosa. 10 to 20 % can occur in the esophageal mucosa. 
Account for 5 to 10 % of cases of upper gastrointestinal hemorrhage. History of 
retching is obtained only 29% of patients. 
 
Bleeding stops spontaneously in 80-90% of patients. 
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3.6.3Duodenal and Gastric ulcers1, 7: 
Ulcer disease is the most common specifically identified cause of acute upper 
gastrointestinal hemorrhage. Peptic ulcer has been reported to be responsible for 
nearly 50% of cases of  upper gastrointestinal bleeding. 
 
The incidence rate of bleeding from duodenal ulcer is approximately twice that of 
gastric ulcers. An ulcer bleeds when it erodes into the lateral wall of a blood 
vessel. 
 
Ulcers located high on the lesser curve of the stomach or on the posteroinferior 
wall of the duodenal bulb are most likely to bleed because of rich vascular supply 
in these areas. 
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3.7 Predisposing factors to ulcer bleeding7: 
• Gastric acid 
• Helicobacter pylori infection 
• Underlying medical and clinical factors 
o Cardiovascular & Cerebrovascular disease 
o Chronic Pulmonary Disease 
o Cirrhosis  
• Drugs like NSAID, glucocorticoids, bisphosphonates alendronate, 
anticoagulants. 
• Ethanol  
• Prolonged hospitalization 
 
3.7.1 Gastric acid1,7 :      
Zollinger-Ellison syndrome – hyper secretory disorder in which ulcers develop 
with high frequency. The ability of antacid therapy alone to heal upper gastro 
duodenal tract ulceration also supports the role of acid. 
 
The best evidence of a role for acid in upper gastrointestinal hemorrhage comes 
from reduction of the risk of bleeding and rebleeding by a proton pump inhibitor. 
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3.7.2 Helicobacter pylori infection5,74: 
The link between H.pylori infection and peptic ulceration is firm. Some studies 
suggest that H.pylori infection increases the risk of ulcer bleeding. The risk of 
Ulcer bleeding in NSAID users infected with H.pylori was nearly twice that of  
uninfected NSAID users. Eradication of H.pylori in patients who are starting long- 
term NSAID treatment has been shown to reduce the risk of an ulcer. 
 
3.7.3 Aspirin and other Non steroidal Anti-inflammatory drugs5,6,74: 
The  most important predisposing factors for ulcer bleeding. The mechanism of 
injury involve reduced production  of cyclo oxygenase generated cytoprotective  
prostaglandins. The risk of bleeding also is increased because of platelet  
dysfunction. 
The risk of gastro intestinal bleeding caused by NSAIDs appears to be dose  
related. The risk of gastric ulceration is increased to a greater extent than that of  
duodenal ulceration. 
The risk of bleeding varies with the individual NSAID; for example, the relative   
risk of bleeding is greatest with azapropazone and piroxicam and less with  
ibuprofen. 
The risk of bleeding is dose dependent. Multiple cofactors contribute to the risk of 
ulcer bleeding associated with NSAIDs. Age >75 yrs, history of heart disease, 
gastrointestinal bleeding were independent predictors of NSAID-induced 
complications 
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Glucocorticoids, alendronate, ethanol appear to potentiate the ulcerogenic effect of 
NSAIDs and may predispose to upper gastrointestinal bleeding. Cyclooxygenase 2 
inhibitors also are associated with an increased risk of ulcer bleeding but to a  
lesser degree than NSAIDs. 
 
3.7.4 Ethanol6: 
Patient who ingest ethanol chronically may have alcohol induced liver disease and  
secondary portal hypertension. Ethanol can induce gastric mucosal injury and 
cause or  potentiate ulcer bleeding. 
 
The relative risk of acute upper gastrointestinal bleeding rose with increasing  
amounts of alcohol consumed. The relative risk of acute upper gastrointestinal  
bleeding caused by aspirin was raised at all levels of alcohol consumption. 
 
3.8.1 Endoscopic stigmata of active or recent bleeding7,8,9 
1. Active arterial spurting 
2. Oozing of blood 
3. Visible vessel 
4. Fresh blood 
5. Blood clot 
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3.9.1 Prognostic Endoscopic characteristics of the ulcer2,3: 
Large ulcer size >1 cm is associated with increased rates of rebreeding & 
mortality. 
 
Endoscopic hemostasis is successful less often for ulcers larger than 2 cm than for 
smaller ulcers. 
 
3.9.2 Ulcer base may have1,7: 
1. Clean base 
 
2. A base with a flat, pigmented spot 
 
3. A base with a visible vessel 
 
4. A base with an adherent clot 
 
5. A base that contains a visible vessel or an adherent clot that is actively  
oozing or an adherent clot that is actively oozing or  spurting. 
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3.10 Other causes:  
3.10.1 Gastric Erosions10: 
Gastropathy most often erosive has been reported to be the cause of bleeding in 
16% of patients with upper gastrointestinal bleeding. 
The bleeding is rarely hemodynamically significant unless the patient has an 
underlying coagulopathy 
  
Sub epithelial gastric erosions develop in the following clinical situations1, 10 
 
1. After ingestion of NSAIDs 
 
2. Stress related mucosal disease 
 
3. With consumption of ethanol 
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Stress related gastric mucosal disease occurs in1, 10: 
 
1. Extensive trauma 
2. Severe burns 
3. Major surgery 
4. Serious medical illness 
¾ respiratory failure 
¾ sepsis 
¾ renal failure 
5. Major neurologic trauma or intra cranial disease 
 
Ethanol6: 
Ingestion of ethanol causes gastric erosions and gastrointestinal bleeding the term 
hemorrhagic gastritis is applied to the subepithelial hemorrhages seen at 
endoscopy in alcoholic patients. 
 
Alcohol consumption is a risk factor for upper gastrointestinal hemorrhage only in 
persons with excessive ethanol consumption (4 or more drinks per day) 
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3.10.2  Duodenitis1: 
 
Rare cause of acute bleeding Risk factors for severe erosive duodenitis include 
NSAID, H.pylori infection and anti-coagulation therapy. 
The bleeding is usually self limited. 
 
3.10.3 Malignancy11: 
Neoplasms of esophagus, stomach, upper small intestine cause acute upper 
gastrointestinal hemorrhage infrequently. 
Often associated with occult, asymptomatic bleeding usually self limited. 
The most common tumor is advanced gastric adenocarcinoma. 
 
 
3.10.4 Vascular lesions: 
Dieulafoy lesion12,69: Also termed exulceration simplex Dieulafoy. 
Abnormally large arteriole that retains the large caliber of its feeding 
vessel as it approaches the mucosa. 
The large vessel compress the mucosa and cause a small erosion, with rupture 
of the vessel into the lumen. 
They account for 6% of cases of upper gastrointestinal hemorrhage. 
Dieulofoy lesions typically are found in the proximal portion of the stomach, 
usually within 6 cm of the gastroesophageal junction. 
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They may be located anywhere in the gastro intestinal tract. Bleeding is often 
massive and recurrent.  
 
The lesion is difficult to identify unless it is actively bleeding. 
 
Endoscopic ultrasonography may be useful for detecting a Dieulafoy lesion in a  
patient with unexplained upper gastrointestinal bleeding. 
 
VASCULAR ECTASIA12: 
Vascular lesions are uncommon but important causes of upper gastrointestinal  
tract bleeding. 
 
The most common are vascular ectasias, most often are found in the stomach or 
duodenum. Vascular ectasias more commonly cause lower gastrointestinal and  
occult bleeding than upper gastrointestinal tract bleeding. 
They are found in  
¾ Renal failure 
¾ Cirrhosis 
¾ Scleroderma 
¾ CREST syndrome ( Calcinosis, Raynauds phenomenon, Esophageal 
dysmotility, Sclerodactyly, Telangiectasis )  
¾ Radiation injury   
¾ Pseudoxanthoma elasticum   
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¾ Ehlers-Danlos syndrome  
¾ Von Willebrands disease  
Vascular ectasia most often appear to be associated with chronic renal failure. 
 
It was more often the cause of bleeding in patients with renal insufficiency than in 
those with normal renal function. 
 
ARTERIO VENOUS MALFORMATION12: 
 
True arteriovenous malformations appear as raised or nodular lesions at endoscopy 
They are rare. Congenital in origin and usually involve the submucosa. 
 
They may be large and involve any portion of the gut. 
 
HEREDITARY HEMORRHAGIC TELANGIECTASIA13: 
Osler-Weber-Rendu disease is an autosomal dominant disorder. 
Characterised by telangiectasias of skin, mucous membranes of gastrointestinal 
tract. 
The peak incidence of bleeding is in the 6th decade of life. 
Bleeding can originate from any site in the gastrointestinal tract. 
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Epistaxis is the most common manifestations of hereditary hemorrhagic 
Telangiectasia and typically occurs before the 2nd decade. 80% of patients have a 
family history of bleeding. 
 
Lack of telangiectasias on the lips, oral and nasopharyngeal membranes, tongue 
and periungual areas cast doubt on the diagnosis. 
 
HEMANGIOMA: 
 
Most commonly identified in the upper small intestine. 
 
These benign vascular tumors are made up of proliferating vessels and appear  as 
single or multiple red, purple or blue nodular lesions. 
 
Blue rubber bleb nevus syndrome is characterized by cavernous hemangiomas of 
the skin, gastrointestinal tract and other viscera. 
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GASTRIC VASCULAR ECTASIA14: 
 
Rarely causes acute gastro intestinal hemorrhage. Characterised by aggregates of 
ecstatic vessels  that appear as red spots on the gastri mucosa. The aggregates are 
arranged in a linear pattern in the antrum of  the stomach , the term gastric antral 
vascular ectasia( GAVE) or Watermelon  stomach. 
 
The red spots may be more diffuse and involve the proximal stomach, the term 
diffuse gastric vascular ectasia is used. 
 
Most common in middle-aged and elderly women with associated achlorhydria,  
 
Atrophic gastritis and cirrhosis. 
 
This lesion is difficult to differentiate from portal hypertensive gastropathy. 
 
Its pathogenesis is unknown. 
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3.11 TREATMENT OF PEPTIC ULCER BLEEDING: 
 
Goals of therapy: 
1. Treat the peptic ulcer &  thus bleeding 
2. To stop active bleeding 
3. To prevent rebleeding 
 
Pharmacologic Therapy: 
Agents to treat active ulcer bleeding are 
 Octreotide 
 Stomastatin 
 Vasopressin 
 Secretin 
 Histamine H2 receptor antagonists 
 Proton pump inhibitors 
 Anti fibrinolytics 
 Prostaglandins 
 
The greatest risk of rebleeding from an ulcer is within the first 72 hours after the  
Initial bleeding episode. 
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The acidic pH retards blood clotting and enhances clot dissolution by proteolytic 
Enzymes like pepsin. 
 
Elevating intragastric pH may facilitate platelet aggregation, further supporting a 
role for acid lowering therapy. 
 
Although H2 receptor antagonists are widely available, non toxic and inexpensive 
the available data donot support their use in patients with ulcer bleeding. 
 
Proton pump inhibitors have significantly better acid reducing characteristics,  
Particularly at high doses, and effective in preventing ulcer bleeding in high risk 
Patients. 
 
The use of nitrovasodilator(Glyceryl trinitrate, isosorbide dinitrate, isosorbide 
Mononitrate or transdermally administered nitroglycerin) was associated with a 
significantly decreased risk  of upper gastrointestinal tract bleeding. 
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3.11 Assessment and resuscitation measures to protect the airway and maintain 
adequate tissue perfusion take priority over all endoscopic procedures. Ideally the 
patients should be haemodynamically stable with a heart rate of less than 100 
beats/ min and systolic blood pressure greater than 100mm Hg. Initially evaluation 
should focus on determining whether the bleed is from the upper or the lower 
gastrointestinal source. A clear nasogastric aspirate may be seen in 14% of 
bleeding duodenal ulcers (DU). 39 Blood transfusions should be instituted in 
patients with postural symptoms and haemoglobin less than 10g /  dl or patients 
with haemoglobin of less than 7 – 8 g / dl even without postural symptoms. 
 
Recommendations of care for severe non – variceal UGI bleed. 40 
1 Protect airway. Intubate for active bleeding or altered mentation 
2 Medical resuscitation with fluids and blood products 
3 Correct coagulopathies (goal : PT<15 sec, platelets > 50,000/cumm) 
4 Lavage with an orogastric tube if blood obscures much stomach 
5 Use therapeutic double – channel videoendoscope 
6 Have therapeutic instrumentation ready before endoscopy 
7  Have a trained nurse assistant available. 
 
 
 
 
 24
 
3.11.2 
Rockall risk scoring system 41,43 
 Score 
Variable 0 1 2 3 
Age (years) <60yrs 60 – 79yrs > 80 yrs  
Shock No shock Tachycardia Hypotension  
Systolic BP 
(mm Hg) >100 >100 <100  
Pulse rate <100 >100 >100  
Co – morbidity Nil  
Cardicfailure 
IHD, Other 
Major co- 
morbidity 
Renal failure,
Liver failure, 
Disseminated
Malignancy 
Diagnosis Mallory – Weiss tear 
All other 
diagnosis 
Malignancy 
of upper GIT  
 Without SRH, no lesion    
Stigma of recent 
bleed (SRH) 
 
None of dark 
spots  
Blood in 
UGIT. 
Adherent 
clot , visible 
or spurting 
vessel 
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3.11.3 PREDICTORS OF RE – BLEED, MORBIDITY AND 
MORTALITY3,4,5 
 
The risk of in – hospital mortality is dependent on age, presence of shock, co – 
morbid condition, stigmata of recent bleed on endoscopy and the underlying 
diagnosis. 
 
Multivariable Scoring System which have been validated for use in 
gastrointestinal bleed include the APACHE scoring system.41 those proposed by 
Zimmerman et al 42 and Rockall et al 43. 
 
Endoscopy provides important risk assessment for rebleed. Rockall Risk Score 
stratifies the risk of death and re – bleed, with a risk of rebleeding of 5% if the 
score is 0 and 40% if score is more than or equal 8. Mortality rate is below 1% and 
as high as 41% if the score is 0 -2 and 8 or more, respectively. 
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3.11.4 
Modified Forrest Criteria 46: 
1. Actively bleeding ulcer. 
1a. Spurting 
1b. Oozing. 
 
2. Non – actively bleeding ulcer 
 
2. a.  Non – bleeding visible vessel 
 
2. b. Ulcer with surface clot. 
 
2. c. Ulcer with red or dark blue spots. 
 
3. Ulcer with clean base. 
Presence of shock and type 1 bleeding peptic ulcer carried a rebleed risk of 80% 
and presence of non – bleeding visible vessel predisposes the patient to a 50% risk 
of further bleed. Ulcer with a clean base (type 3) and ulcers with red or dark blue 
spots (type 2c) rarely re – bleed during hospitalization. Bleeding peptic ulcer in the 
posterior duodenal bulb and proximal gastric lesser curve are located near major 
vessels and are associated with higher re – bleed rates and are more likely to cause 
death 43,44. 
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3.11.5 Predictors of Mortality 
 
Patients characteristic that have been reported to be associated with increase in 
mortality are42,44: 
 
 
1. Age 
2. onset of bleeding 
3. co – morbidity 
4. hypotension and shock at presentation  
5. Fresh bleed in Ryle’s tube aspirate 
6. Haemoglobin level.at presentation and on serial follow – up 
7. Number of packed cells transfusions  
8. Corticosteroids  
9. Combined use of aspirin and oral anticoagulants. 
Patients who start bleeding during hospitalization (secondary bleeding) have a 
significantly higher mortality as compared to those who bleed prior to 
hospitalization (primary bleeding). 47 This is primarily because of presence of co – 
morbidity factors in hospitalized patients. Mortality is significantly higher in 
patients with comorbid illness which include CNS diseases, hepatic insufficiency, 
pulmonary diseases, cardiac diseases, renal failure, physiological stress and 
cancer. The mortality increases with increase of co – morbid conditions.43,47 
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Use of low dose aspirin is associated with moderately reduced risk of severe 
bleeding and a decreased mortality from GI bleeding. 48,49. Possible explanation is 
the increased patient awareness and vigilance and propensity to bleed from minor 
lesions with aspirin therapy. 
 
3.11.6 Predictors of Rebleeding50 
As many as 10% patients rebleed after endoscopic therapy.  
1. Failure of therapy and recurrent upper GI bleeding is associated with an 
increase in mortality. Apart from the  
2. Endoscopic stigmata of recent ulcer bleed, many independent factors 
predict the rebleeding risk. These include  
3. Age more than 65 yrs.  
4. Tachycardia and shock at admission,  
5. Obesity, haematemesis,  
6. Specific ulcer location  
7. Diameter more than 2 cm.  
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3.11.7 Helicobacter pylori and recurrence of ulcer bleed54,56 
 
H. pylori eradication in patients with bleeding ulcers is known to reduce the 
recurrence of bleeding. In various small studies with a follow up period ranging 
from 4 to 48 months, the rate of duodenal ulcer relapse and rebleeding was 
significantly reduced in patients with successful eradication of H. pylori . 
 
In patients with bleeding peptic ulcer associated with H. pylori, eradication should 
be confirmed by urea breath test or the biopsy urease test at endoscopy. 
 
3.12 ENDOSCOPIC THERAPY 
 
Peptic ulcer disease accounts for about two third of  all cases of upper gastro 
intestinal haemorrhage as diagnosed on upper GI endoscopy. 57. Forrest type 3 
(clean base) ulcers on endoscopy are seen in approximately 30 – 50% of peptic 
ulcer bleeds. These along with type 2c ulcers don’t require any further endoscopic 
therapy. 
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For ulcers with active bleed or evidence of stigmata of recent bleed, the 
endoscopic modalities available are listed below. 
 
3.12.1 Endoscopic Therapies Used for Ulcer Bleeding  
 
Injection: 
¾ Epinephrine 
¾ Saline 
¾ Water 
¾ Ehanol 
¾ Sclerosants 
¾ Fibrin glue 
¾ Thrombin 
Thermal methods 
• Bipolar or multipolar electrocoagulation 
• Heater probe 
• Laser photocoagulation 
• Monopolar electrocoagulation 
Hemoclips 
Argon plasma coagulation 
Band ligation 
Endoloops 
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Endoscopy has beyond doubt reduced morbidity, hospital stay, risk of recurrent 
bleeding and need for surgery in patients with non – variceal upper GI bleed. Early 
endoscopy (within 24 hours) in an intensive care setting in patients of NVUGIB 
significantly effects the transfusion requirement, duration of ICU stay and rebleed 
rate.60. 
3.12.2 
Endoscopic stigmata of ulcer haemorrhage, their prevalence, risk of rebleeding 
and effect of endoscopic therapy on rebleed rates is listed out below. 
 
Outcome of Endoscopic Therapy for Bleeding Peptic Ulcers According to 
Their Endoscopic Appearance.    1 
 
Rebleeding    
Rate (%) 
Surgery 
Rate (%) 
Mortality 
Rate (%) Appearance Frequency (%) 
No ET      ET No ET       ET 
No ET      
ET 
Active 
bleeding 
18 55              20 35               7 11           <5 
Visible vessel 17 43               15 34               6 11           <5 
Adherent clot 
 
15 22               5 10               2 7                <3
Flat spot 15 10               <1 6            <1 
3            
<1 
Clean ulcer 
base 
35 <5               NA 0.5          NA 
2           
NA 
 
 
 
 
] 
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3.12.3 Haemoclips versus hypertonic saline – epinephrine injection. 
 
Injection therapy with Epinephrine at concentration of 1:10,000 or 1:20,000 using 
23 to 25 – guage sclerotherapy needle is widely used. It causes local tamponade, 
vasoconstriction and enhances platelet aggregation to achieve local haemostasis. 
Epinephrine is injected into the submucosa in 0.5 – 1.0 ml increments in all four 
quadrants around the bleeding site. Endoscopic metallic clips were compared in an 
RCT to hypertonic saline – epinephrine injection versus the combination of both 
by Chung et al61. The authors achieved intial haemostatis in 95% of patients with 
active bleeding or visible vessel with a tendency to produce less rebleed rates and 
surgeries with the use of haemoclips. Haemoclips have their technical and 
practical limitations that include need for special training, special devices, 
possibility of clip tearing the vessel wall and inability to stop bleed in arteries 
greater than 1 – 2 mm size. 
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3.12.4 Ethanol injection versus Haemoclips 
Injection of alcohol carries a high risk of ulceration and perforation, thus only 
small volume (maximum of 2 ml) is recommended. A retrospective study reported 
similar haemostasis rates with haemoclip application and ethanol injection 
group.62. Alcohol injection produces dehydration and fixation of tissue and 
subsequent necrosis and ulceration. Because of this risk of ulceration and 
perforation only small dose of alcohol is used. 
Other sclerosants such as sodium tetradecyl sulphate, polidocanol and 
ethanolamine have been used alone or in combination with epinephrine for 
injection therapy of peptic ulcer bleed. 
3.12.5 Heater probe versus Haemoclips 
Thermocogulation when compared to haemoclips for visible or bleeding vessel in 
the ulcer base revealed a similar death rate and surgery rates 63. The same study 
reported the superiority of haemoclips in prevention of rebleed (2% rebleed rate 
with haemoclip and 21% rebleeding in the heater probe group) and lower 
transfusion requirement and hospital stay. Haemoclip application failure in six out 
or 56 patients was attributed to the ulcer site (proximal posterior gastric wall or 
posterior wall of duodenal bulb) or size of ulcer greater than 15mm. 
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 Butyl 1 – 2 cyanoacrylate versus hypertonic saline – epinephrine injection 
Butyl 1 – 2 cyanoacrylate is a liquid glue that polymerizes on contact with blood. 
Lee et al63 reported similar initial haemostasis rates with both butyl 1-2 
cyanoacrylate and hypertonic saline – epinephrine injection therapy in actively 
bleeding peptic ulcers but the glue injection group had a significantly lower 
rebleeding rate (14% vs 42%). The rebleeding rates were similar in non-bleeding 
visible vessel ulcers in both groups. Glue embolization and perforation are the two 
feared complications with glue injection. 
 
3.12.6 Fibrin Glue and hypertonic saline – epinephrine injection 
Theoretically the injection of fibrin glue to halt peptic ulcer bleeding may be safer 
than other sclerosing agents as it would not cause necrosis or degeneration. 
However, results from a prospective randomized control trial conduced by Song et 
al comparing fibrin glue and hypertonic saline – epinephrine injection suggested 
no statisfically significant difference between the two modalities of therapy64. 
 
3.12.7 Combined modalities 
There is trend towards combined use of two endoscopic modalities using injection 
and mechanical or injection and thermal probe therapy in actively bleeding peptic 
ulcer 61,66. Rebleed rates with combined therapy using adrenaline injection and 
thermocoagulation showed a trend towards decreased rebleeding compared to 
injection alone when dealing with spurting peptic ulcer haemorhage.66 
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3.13.DRUG THERAPY 
Intravenous high dose omeprazole (80 mg bolus followed by 8 mg / hr), after 
endoscopic haemostatis has been achieved in a peptic ulcer bleed reduces the risk 
of rebleeding and need for endoscopic re – treatment and surgery.67 Use of H2 
receptor antagonists is not supported by clinical trials. 
 
Oral omeprazole in the dose of 40mg twice a day has been reported to decrease the 
risk of rebleeding in patients with stigmata of recent bleed without endoscopic 
therapy by Khuroo et al.68 
 
3.14 RECURRENT HAEMORHAGE 
Rebleeding after successful endoscopic therapy range from 10 – 20%. In a 
prospective, randomized study, Lau et al compared endoscopic retreatment with 
surgery after initial endoscopy for recurrent ulcer bleed.53 In patients ulcer and 
recurrent bleeding after initial endoscopic control of bleeding, endoscopic 
retreatment reduced the rate of surgery and complications. Second endoscopic 
procedure avoided surgery in 73% of rebleed patients. Multivariate analysis 
showed two predictors of rebleed; ulcer diameter more than 2cm and hypotension 
during rebleeding. Patients who rebleed after second endoscopy should be 
subjected to either surgery or embolization for haemostasis. 
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3.15 NON – ULCER NVUGIB 
 
3.15.1 Dieulafoy’s lesions 
 
A Dieulafoys lesions is marked by the presence of large, submucosal artery that 
protrudes through the mucose, is not associated with peptic ulcer and cause 
massive GI bleeding. Endoscopic therapy with injection therapy, thermal probes, 
clipping devices and band ligation has been evaluated. Narayan et al reported a 
rebleeding rate of 50% with single modality therapy.[31]. A combined used of 
epinephrine injection and heater probe, as recommended for active bleeding or 
adherent clots, achieves an intial haemostatis in 90% and a rebleed rate of less 
than 20% of patients [2]. Tattooing with India Ink around the arterial spurter 
assists the surgeon in identifying the bleeding site at laparotomy. 
 
 
Endoscopic band ligation for Dieulafoy’s lesion in a case series was successfully 
used in 3 out of 4 patients [32]. One out of three successfully banded patients had 
rebleeding from the post banding ulcer site, which was managed successfully with 
epinephrine injection. 
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3.15.2 Mallory – Weiss Tears 
 
Mallory – Weiss mucosal laceration are usually secondary to vomiting and result 
in self limiting, small volume bleed. Haemorrhage is usually mild and self – 
limiting. Jensel et al prospectively evaluated endoscopic therapy for actively 
bleeding Mallory – Weiss tears, without portal hypertension. [33]. They achieved 
a 100% haemostasis rate compared with 40% for medical therapy. Twenty percent 
of patients with visible non-bleeding vessel or adherent clot rebleed. They 
recommend the use of low power settings of light touch bipolar coagulation, or 
ephinephrine injection only in actively bleeding tears. Patients with portal 
hypertension and actively bleeding. Mallory – Weiss tears should be subjected to 
therapy for the adjacent varix and not bipolar coagulation. 
 
Haemclipping has been successfully used in actively bleeding Mallory – Weiss 
tears or tears with a visible vessel or fresh adherent clot. In a series of 58 patients 
of whom 26 had high – risk signs on endoscopy 2.8+1.6 clips were deployed with 
100% technical success and haemostasis. No rebleeding was noticed in any of the 
patients on a 2 months follow – up [34]. 
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Endoscopy is the key diagnostic tool for management of upper gastrointestinal 
bleeding. In addition it provides a unique therapeutic opportunity which has over 
the years reduced the need for emergency surgery, but the impact on survival is 
less dramatic with the mortality from severe UGI bleeding remaining fairly 
constant. Optional use of endoscopic therapeutic modalities shall continue to play 
a pivotal role in management of UGI bleed in the years to come. 
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3.16 Portal Hypertension: 
 
3.16.1 Definition:   Elevation of the hepatic venous pressure gradient (HVPG) to  
> 5mmHg. 
 
3.16.2 Classification: 
Prehepatic 
 
¾ Portal vein Thrombosis 
 
¾ Splenic vein Thrombosis 
 
¾ Massive Splenomegaly (Banti’s syndrome) 
 
Hepatic 
Pre sinusoidal 
 
• Schistosomiasis 
 
• Congenital hepatic fibrosis 
 
Sinusoidal 
 
• Cirrhosis – many causes 
 
• Alcoholic hepatitis 
 
Post sinusoidal 
 
• Hepatic sinusoidal obstruction (Veno occlusive disease) 
Post hepatic 
 
• Budd-Chiari Sydrome 
• Inferior vena cava webs 
• Cardiac causes 
 
o Restrictive Cardiomyopathy 
 
o Constructive pericarditis 
 
o Severe Congestive heart failure 
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3.16.3 Factors of risk of variceal bleeding: 
 
• Severity of cirrhosis – CHILD’S class 
 
• Height of wedged hepatic vein pressure 
 
• Size of the varix 
 
• Location of the varix 
 
• Endoscopic stigmata like 
 
o Red wale signs 
 
o Hematocystic spots 
 
o Diffuse erythema 
 
o Bluish color 
 
o Cherry – red spots 
 
o White – nipple spots 
 
 
• Tense Ascites 
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3.16.4 SITES OF  COLLATERAL FORMATION: 
 
 
Distal Oesophagus & Proximal Stomach :  Gastro esophageal varices are the  
Major collaterals formed between the portal venous system and systemic venous 
system . 
 
Umbilicus :  Vestigeal umbilical vein communicates with the portal vein and 
gives rise to prominent collaterals around the umbilicus (Caput Medusae) 
 
Retroperitoneum :  Collaterals communicate between the ovarian vessels and 
iliac veins. 
 
Rectum :  Inferior mesenteric vein connects with pudendal vein and result in 
Rectal varices. 
 
Measurement of   Portal pressure : 17 
 Hepatic Vein Pressure Gradient – The most commonly used indirect 
method  
 Splenic Pulp Pressure 
 Portal Vein Pressure  
 Endoscopic variceal Pressure 18 
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3.16.5 Detection of varices : 
 
¾ Upper gastrointestinal endoscopy 19 
¾ Ultrasonography 
¾ Computed Tomography 
¾ Magnetic Resonance Imaging 
¾ Endoscopic Ultrasonography 
 
3.16.6 Clinical assessment of patients with portal hypertension – related 
bleeding: 
 
History of hemetemesis and Melena 
Peripheral stigmata of liver disease like 
 
¾ Jaundice 
¾ Spider telangiectasias 
¾ Palmar erythema 
¾ Dupuytren’s Contracture 
¾ Parotid enlargement 
¾ Testicular atrophy 
¾ Loss of secondary sexual characters 
¾ Ascites 
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¾ Encephalopathy 
¾ Features of portal hypertension like splenomegaly & ascites 
¾ Caput Medusae around the umbilicus 
¾ Venous hum in the epigastrium due to the collateral flow in the falciparum 
ligament. 
 
3.16.7 Laboratory studies:1 
 
Evidence of hepatic synthetic dysfunction 
 
o Prolongation of Prothrombin time 
o Hypoalbuminemia 
o Hyperbilirubinemia 
o Anemia 
 
Feautures of Hypersplenism 
o Anemia ,  
o Thrombocytopenia, 
o Leukopenia 
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Abdominal imaging : 
 
• Reveal splenomegaly,  
• collateral vessels,  
• abnormal liver echotexture  
• Contour and ascites. 
 
3.16.8 Treatment of Portal Hypertension: 
Pharmacologic Therapy: 1,15,20,16 
 
Drugs that decrease portal blood flow 
o Non-Selective beta adrenergic blocking agents  
o Vasopressin 
o Somatostatin and in analogs 
 
Drugs that decrease intrahepatic resistence 
o Nitrates 
o Alpha1 adrenergic blocking agents (Prozosin) 
o Angiotensin receptor blocking agents 
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3.16.9 Endoscopic therapy: 
Sclerotherapy:21 
Available evidence does not support emergency sclerotherapy as first line 
treatment of variceal bleeding. 
 
Sclerosants used include Sodium tetradecyl sulfate, Sodium morrhuate, 
Ethanolamine oleate, Absolute alcohol. 
Complications include 
o Retrosternal discomfort 
o Sclerosant induced esophageal ulcer related bleeding 
o Stricture and perforation 
Variceal ligation:25 
Preferred endoscopic modality for control of acute bleeding and prevention of 
rebleeding. 
The procedure involves suctioning of the varix into the channel of an endoscope 
and  Deplaying a band around the varix.  The band strangulates the varix causing 
thrombosis. 
Varices in the mid or proximal esophagus not need to be banded. Complications 
include Esophageal ulcers, strictures, dysmotility. 
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TRANS JUGULAR INTRA HEPATIC PORTA SYSTEMIC STENT 
SHUNT:22 
 
Reduces elevated portal pressure by creating a communication between the hepatic 
vein and intrahepatic branch of the portal vein. 
 
TIPS function as a side to side portacaval shunt. The procedure involves 
cannulation of Hepatic vein through a trans jugular approach and using a Rosch 
needle, the portal vein is  cannulated. A guide wire is then passed to connect the 
hepatic vein and a branch of the Portal vein. Following dilation  of the tract, a stent 
is placed and dilated as required to reduce the portacaval pressure gradient to 
below 12 mmHg.22 
 
The stents used are Wall stent, Palmaz stent and coated stent with Polytetrafluoro -
ethylene. 
 
The most common indications for placement of a TIPS is refractory variceal 
bleeding when pharmoco and endoscopic therapies have failed 24, especially in 
patients with  CTP class B or C cirrhosis. 
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Surgery: 
 
Non – shunt Procedures: 
 
¾ Esophageal Transection 
¾ Devascularization Procedures 
 
Porto systemic shunts 
 
¾ Selective shunts 
¾ Partial porto systemic shunts 
 
3.17.1 Esophageal varices:23 
 
Present in approximately 40% of patients with cirrhosis and upto 60% in cirrhosis 
with Ascites. New varices will develop at a rate of 5% per year. 
 
Progression of small varices to large varices occurs at a rate of  10 % to 15% per 
year and  is related to the degree of hepatic dysfunction. 
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Upto 25% of newly diagnosed varices will bleed at 2 years. The best predictor of  
bleeding appears to be variceal size. The risk of bleeding in patients with varices  
less than 5mm in diameter is 7% at 2 years and it is 30% if size is more than  
5mm. 
 
Risk of bleeding is virtually absent when HVPG is < 12mmHg. 
 
Approximately one half of patients with a variceal bleed stop spontaneously 
because hypotension leads to Splanchnic vasoconstriction which results in 
decrease in Portal pressure. Excessive transfusions increase the chance of 
rebleeding. 
 
Failure to control bleeding at 5 days occurs in 24 
9 Active bleeding at endoscopy 
9 Lower initial hematocrit level 
9 Higher serum aminotransferases level 
9 CTP class 
9 Bacterial infection 
9 HVPG  >20mmHg 
9 Portal vein thrombosis 
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One third of patients will rebleed within the next 6 weeks; 40% will take place 
within 5  Days of the initial bleed. 
 
Predictor of rebleeding: 24 
• Active  bleeding at endoscopy  
• Bleeding  from gastric varices 
• Renal insufficiency 
• HVPG >20mmHg 
 
3.17.2 DETECTION OF ESOPHAGEAL VARICES THROUGH UPPER 
GASTRO INTESTINAL ENDOSCOPY: 
 
Endoscokpic grading of esophageal varices compiled by the Japanese Research 
Society Portal Hypertension. 
The descriptors  include: 
o Red color signs,  
o color of the varix,  
o form of  the varix, 
o  location  of  the  varix. 
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Red color signs: 
 
• Red wale markings – Longitukdinal whip-like marks on the varix. 
• Chery red spots – 2 to 3 mm or less in diameter. 
• Hematocykstic spots – Blood filled blisters 4 mm or greater in diameter. 
• Diffuse redness. 
 
Colour: 
 
¾ White or blue. 
 
Form of  the varix: 
Grade I : Small and straight 
 
Grade II : Tortuous and occupying less than one third of the esophageal lumen. 
 
Grade III : Large and occupying more than one third of the esophageal lumen . 
 
Location :  
o Lower third, middle third, upper third of the esophagus 
 
 
 51
 
 
SIZE: 
 
Size of the varices in the lower third of the esophagus is most important. 
 
¾ Small varices – Occupying lesss than one third of the lumen <5mm in 
diameter. 
¾ Large varices - >5mm in diameter. 
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Repeat endoscopy in 
2-3 years  
Repeat endoscopy in 
 1 – 2 years 
consider base line 
HVPG 
Continue therapy Perform EVL 
 
 
3.17.3 Primary Prophylaxis to prevent first episode of variceal bleed1 
 
Upper Endoscopy 
 
 No varices      
 
         Small  esophagel  
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes         No 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Large esophageal 
varices 
B- Adrenergic 
blockers 
Repeat HVPG in 1 
month 
HVPG ↓ < 12 mmHg 
or HVPG↓ >= 20% 
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Resuscitation  
Vasoactive agent 
(eg. Octreotide, antibiotic eg. Norfloxacin) 
 
 
 
 
Upper endoscopy 
Variceal ligation (or sclerotherapy) 
Balloon tamponade 
Secondary prophylaxis 
Bleeding control 
Balloon tamponade 
CTP Class A CTP Class B/C 
3.17.4 Algorithm for the Management of acute variceal bleeding1 
 
Active bleeding from Esophageal varices 
            
            
            
            
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                         Yes 
                    No 
 
 
 
 
 
 
 
                                              No                                   Yes 
                                                                           Secondary prophylaxis 
            
            
            
           
 
 
 
                      TIPS                                                                
 
Bleeding controlled 
Surgical Portosystemic  
shunt or TIPS 
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3.18.1  GASTRIC VARICES27,28 
The most widely used classification of gastric varices is the sarin classification. 
  
The type1 gastro oesophageal GOV-I extend 2 – 5 cm below the gastro 
oesophageal junction and are in continuity with oesophageal varices  
 
Type 2 gastro oesophageal varices (GOV2) are in the fundus of the stomach and 
in continuity with oesophageal varices  
 
IGV1: Varices that occur in the fundus of the stomach in the absence of 
oesophageal varices. 
 
IGV2 – Varices that occur in the gastric body antrum, or pylorus 
 
GOV1 comprises approximately 70% of all gastric varices. 
 
Approximately 25% of patients  with portal hypertension have gastric varices, 
most commonly GOV1 
 
Intrahepatic causes of portal hypertension maybe associated with both GOV1 and 
GOV2. Splenic vein thrombosis usually results in IGV1, but the most common 
cause of fundal gastric varices may be cirrhosis. 
 
Bleeding is more common in patients with GOV2 and IGV1,then in those with 
other types of gastric varices. 
Gastric Varices tend to the larger in diameter than oesophagheal varices. 
 
Bleeding from gastric varices has been described with an HVPG less than 12 
mmHg. 
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3.18.2 ALGORITHM FOR THE MANAGEMENT OF GASTRIC VARICEAL  
BLEEDING 
 
            
            
            
            
    
 
 
 
 
 
 
 
yes      No    
                                                                 No 
                                                                   
 
 
 
 
 
 
 
                          Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gastric Variceal Bleeding 
Resuscitation Vaso active agent (eg. 
Octreotide) Antibiotic (eg Norflocacin) 
Endoscopic therapy possible  
Bleeding 
Controlled
TIPS TIPS 
Cyanoacrylate 
available 
Consider obliteration 
of varices 
CTP Class A CTP Class 
Borc 
Surgical Porto 
Systemic Shunt 
TIPS 
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4.1Materials and methods 
 
 
Place of study                        :  Department of Internal Medicine , 
 
                                                  Thanjavur Medical college hospital , 
 
                                                  Thanjavur 
 
Type of study                        :   Prospective study 
 
Period of study                      :   Dec 2007 to Nov 2008   
 
Ethical Committee approval  :  The  present study was approved by the 
                                                   Ethical Committee 
 
Collaborating Department     :   Department of Medical Gastro 
                                                   Enterology 
 
Consent                                  :   Informed consent was obtained from the 
                                                   Participants 
 
 
4.2 Selection of patients 
 
Hundred patients satisfying the following inclusion criteria and not 
 
having any of the exclusion criteria were taken up for the study. 
 
4.2.1Inclusion criteria 
 
(1) All adult patients of both sexes who were giving definite history 
of vomiting of frank blood or coffee ground coloured vomit and/ 
or passed dark coloured stools were chosen for this study. 
 
(2) Inpatients admitted for other illnesses and who subsequently 
developed UGI bleeding  following prescription with drugs 
like aspirin, other NSAIDS, steroids, anticoagulants and  
               other gastro toxic drugs were also included  
 
(3) Inpatients  who developed UGI bleed after administration for 
severe medical illness like respiratory failure , sepsis. 
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4.2.2 Exclusion criteria 
 
 The following groups of patients were excluded from this study after 
 
detailed history taking, clinical examination and investigations because 
 
of the confounding factors which will interfere with the results. 
 
(1) Patients with history of epistaxis  and bleeding gums 
 
and subsequently developed spurious hemetemesis. 
 
(2) Bleeding and clotting disorders 
 
(3) Hematological disorders 
 
 
(4) Critically ill patients those who could not be mobilized  
 
for UGI  endoscopy 
 
4.3 Study method 
 
4.3.1 History 
 
Patients characteristics like age and sex were noted.  Detailed history regarding the UGI 
 
 bleeding like number of times of hematemesis  approximate quantity of  blood  
 
vomited each time, associated with malena  or presenting with  malena alone  were 
 
 obtained.  Symptoms of common  diseases that can lead to UGI bleeding and detailed 
  
history of  drug intake like aspirin, other NSAIDs , steroids and symptoms due to blood 
 
 loss were  recorded in the questionnaire. 
 
Detailed history asked from the patients regarding the risk factors of UGI bleeding: 
 
(1) Known peptic ulcer disease (diagnosed by  a physician or a gastro 
 
enterologist) 
 
(2) Alcoholism  (those who are consuming alcohol at least 100ml/day 
 
Regularly for >3 months ) 
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(3) Smoking (those patients who are smoking one or more beedies or  
 
cigarettes per day regularly for >3 months) 
 
(4) Stress and serious systemic illnesses of the patients 
 
(5) Intake of drugs that may cause UGI bleeding when taken like 
 
NSAIDs, steroids, bisphosphonates and chemotherapeutic agents 
 
were  obtained. 
 
 
4.3.2 Clinical examination 
 
Routine general and systemic examination of the patients was carried out  
With the aim of  
 
(1) Assessing the general condition of the patient 
 
(2) Confirmation of UGI bleeding by Ryle’s tube aspiration . 
(3) Assesing severity of blood loss  
 
(4) Assessing the common causes of gastro intestinal bleeding like 
 
Cirrhosis of liver with portal hypertension. 
 
(5) Ruling out hematological disorders causing  UGI bleed. 
 
4.3.3 Laboratory investigations 
 
Routine urine and blood investigations to find out  hemoglobin status, blood  Grouping 
and typing for transfusion, to find out renal failure, hepatic failure, bleeding and clotting 
disorders and hematological disorders were carried out. 
 
 
 
 
 
 
 
 
 
 
 59
 
4.3.4 Upper gastrointestinal endoscopy 
 
Endoscopy was done for all the patients after overnight fasting, using  PENTAX video 
endoscopic system , to directly visualize the mucosa of  the esophagus, stomach and 
duodenum, like varices, ulcers , erosions. 
 
The endoscopic stigmata of active or recent hemorrhage  and endoscopic prognostic  
features like number of ulcers, site and location of ulcers, size of ulcers, bleeding or not 
 healing or not, clean base of the ulcer or adherent blood clot, oozing of  blood from the 
 
 ulcer base and about visible blood vessel were studied. 
 
The site, grading of varices were studied and search for rare causes for  UGI bleed were 
made. 
 
 
4.4 Study approach 
 
Number of patients affected, were studied with respect to age group, approximate 
 
 quantity of total blood loss,  prevalence of endoscopic findings in UGI bleed.  
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RESULTS AND OBSERVATIONS 
 
5.1. SEX DISTRIBUTION  
 
In this Study of 100 cases of UGI Bleed the Sex distribution is observed as  
 
Table-5.1 
 Number of cases  % 
MALE 72 72 % 
FEMALE 28 28 % 
TOTAL 100  100 % 
 
 
 
Figure-5.1 
72%
28%
Male Female
 
 
In the study among 100 patients, 72 were males and 28 were females. 
 
 61
 
5.2. AGE DISTRIBUTION  
 
In this Study of 100 cases of  UGI Bleed the Age distribution in each Age 
Group is  observed as  
 
Table-5.2 
 
S.No Age Group Male Female Total 
1 Age<20 2 1 3 
2 Age 20 -34 11 3 14 
3 Age 35 – 49 20 11 31 
4 Age 50 – 64 27 11 38 
5 Age 65 - 79 12 2 14 
Total 72 28 100 
 
Figure-5.2 
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It was found that majority of patients (38%) were in the age group of 50- 64 years. 
The highest age of patient participated in study was 75 years and lowest age of patient 
was 15 years. 
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5.3. QUANTITY OF BLOOD LOSS 
In this study UGI bleed the approximate quantity of blood loss is observed as 
 
 
Table-5.3 
S.No Quantity of blood loss  Number of Patients 
1. < 100 ml 60 
2. 100 to 1000 ml 28 
3. > 1000 8 
4. H/o of Malena alone 4 
 
Figure 5.3 
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It was found that majority of patients 60 % were having minor UGI bleed with 
 < 100ml of blood less. 
Only 8% of the patients had major UGI bleed and four patients had only malena. 
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5.4 FREQUENCY OF HEMETEMESIS 
 
In this Study of 100 cases of UGI Bleed the frequency of Hematemesis is observed as,   
 
TABLE-5.4  
 
S.No Number of Bouts of Hematemesis Number of Patients 
1. One 34 
2. Two 42 
3. Three 13 
4. Four 8 
5. Five 3 
 
Figure 5.4 
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It was found that percentage of patients with two episodes of hematemsis 
was more with 42%. 
 The maximum frequency of hemetemesis was five. 
Single episode of hemetemesis was observed in 34 partients (34%) 
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5.5. SEVERITY OF LESION  
 
In this Study in UGI bleed frequency of severity of clinical presentation is observed as 
Table-5.4 
Sl.No Nature of Lesion Minor Moderate Major Melena only 
1 Gastric Ulcer  15 10 1 0 
2 Duodenal  Ulcer  14 7 1 0 
3 Gastric Erosion 7 3 0 0 
4 Oesophageal Varices 4 2 3 3 
5 Oesophagitis 7 1 0 0 
6 Duodenitis 4 0 0 0 
7 Fundal Varices 2 1 1 0 
8 Hemorrhagic Gastritis 0 1 0 0 
9 Esophageal ulcer 0 1 0 0 
10 Carcinoma Stomach 1 0 0 1 
11 Gastric Ulcer + Duodenal Ulcer 4 0 2 0 
12 Varices + Peptic Ulcer 2 2 0 0 
  Total 60 28 8 4 
 
 
Figure-5.5 
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It was observed that 60% of lesions were presented as minor UGI belled and 28% as moderate 
UGI bleed. 
Only 8% of lesions presented with major UGI bleed 
 
 Varices (50%) were the most common lesion found in major UGI bleed. 
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Figure-5.6 
 
Prevalence of Endoscopic Lesion
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Carcinoma Stomach Gastric Ulcer + Duodenal Ulcer Varices + Peptic Ulcer
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5.6. Prevalence of Endoscopic Lesion 
 
 
Table- 5.5 
In this study of UGI bleed the prevalence of nature of lesions on endoscopy is observed as  
 
< 20 20-34 35-49 50-64 65-79 Sl.No Nature of Lesion 
M F M F M F M F M F 
Total 
% 
1 Gastric Ulcer  Alone 1 - 4 1 3 2 8 3 4 - 26%
2 Duodenal  Ulcer Alone - 1 3 1 4 3 5 2 3 - 22%
3 Gastric Erosion - - 1 - 2 1 3 1 1 1 10%
4 Oesophageal Varices 1 - 1 1 3 1 3 1 1 - 12%
5 Oesophagitis - - 1 - 2 1 1 1 2 1 8%
6 Duodenitis - - - - 1 - 2 1 - - 4%
7 Fundal Varices - - - - 1 1 1 - 1 - 4%
8 Hemorrhagic Gastritis - - - - - - 1 - - - 1%
9 Esophageal ulcer - - - - 1 - - - - - 1%
10 Carcinoma Stomach - - - - 1 - 1 - - - 2%
11 Gastric Ulcer + Duodenal Ulcer - - 1 - 1 1 1 2 - - 6%
12 Varices + Peptic Ulcer - - - - 1 1 1 - - 1 4%
Total 100% 
 
 
In this study among 100 patients , 26 patients (26%) had gastric ulcer 
alone, 22 patients (22%)had duodenal ulcer alone and 6 patients had both 
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gastric ulcer and duodenal ulcers (6%), collectively comprising most 
common cause of UGI bleed contributing 54% of the total . 
     
 
 
 It was found that Esophageal varices were the second most common 
lesion contributing 12% of UGI bleeding. 
 
 4 cases(4%) of fundal varices were noted  
 
 The other acid peptic disorder lesions observed were gastric erosion 
10%, Esophagitis  8% Duodenitis 4%,Hemorrhagic gastritis 1% Esophageal 
ulcer 1%  
 
 Peptic ulcer were noted in 4 patients (4%) of varices. 
 
 Multiple lesions were observed in 10% of cases  
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5.7. Prevalence of Acid Peptic Lesion  
In this Study of UGI Bleed the prevalence of acid peptic lesion is   observed as  
Table-5.6 
 
Sl.No Acid peptic disease  Male Female Total % 
1 Gastric Ulcer Alone 20 6 26 37%
2 Duodenal Ulcer Alone 15 6 22 31%
3 Gastric Erosion 7 3 10 14%
4 Duodenitis  3 1 4 5% 
5 Hemorrhagic Gastritis 1 0 1 1% 
6 Oesophagitis 6 2 8 11%
        7 Esophageal ulcer 1 0 1 1% 
 Total 72  
Figure-5.7 
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It was found that gastric ulcer was present in 26% patients (37%) among 72 patients of 
with single acid peptic disease lesion only. 
Duodenal ulcer 31% was the second common lesion gastric erosion was seen in 14% of 
patients with acid peptic lesion. 
Four cases were due to duodenitis 
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DISCUSSION 
 
 
6.1. Sex 
 
Out of one hundred patients studied, seventy two were male patients  and twenty 
eight were female. In a Scandinavian study, it was found that incidence of  UGI 
bleeding was twice as high among men as among women  (oliver et al.,  1997 ) . 
 
6.2. Age 
 
The percentage of number of patients in the age group of equal to or above 50 yrs 
of age was 52 % comprising  more than ½ of all the patients.  In this study it was 
found that elderly patients were bleed in a high incidence because the frequency of  
bleeding is directly related to the duration of  the disease. 
 
The increased incidence of  UGI bleed in elderly individuals were also due to 
frequent prescription of NSAIDs and aspirin for their cardiac problems  and the 
relative risk was 2.0 times higher than the others. 
 
In the early study by Griffin et al., (1991) the relative risk for elderly patients with 
age group > 60 years was 3.8 times than the others. 
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6.3. Severity of hemetemesis 
Percentage of patients with one or two episodes of hematemesis was 76%.  60% of 
the patients admitted for UGI bleed were having minor UGI bleed (<100 ml ).  
Only 8 % of the patients had severe UGI bleeding (1000ml) in the present study 
and majority of the patients 50% were found to have oesophageal varices and 
fundal varices on endoscopy. 
 
In this study among 8 cases of major UGI bleed , Esophageal varices (3 cases) and 
Fundal  varices (1 case)  contributes 50% of total number of major UGI bleed. 
 
Rupture of varices is the most common cause of life threatening hemorrhage. Risk 
of bleeding is greatest when varices are large and when they are prominent in the 
gastric fundus. (Lebrec, 1980) 34.  
 
6.4. Endoscopic findings 
In the present study, patients had undergone delayed UGI endoscopy by three to 
five days . The prevalence of nature of lesions is as follows. 
 
6.4.1. Peptic ulcer: 
In this study, gastric ulcer alone  26 cases (26%), duodenal ulcers alone 22 cases 
(22%) and both lesions in a same patient 6% collectively remain the most common  
cause of UGI bleed  with total of 54% . 
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In American Society for Gastrointestinal Endoscopy ( Gilbert DA, Tedesco F J, et 
al39) Chronic gastric and duodenal ulcers collectively remain the most common 
cause of hematemesis and melena. 
 
Rockall et al; GF Longstreth:2,43AMJ Gastroenterol 1995 reported peptic ulcer was 
the  most common lesion on endoscopy in cases with UGI bleed. 
 
The increased frequency of gastric ulcers bleed than duodenal ulcers is likely to be 
due to gastric ulcers have a slightly greater tendency to bleed than duodenal  
ulcers, 23.7% compared with 19.1%. 
 
6.4.2. Oesophageal Varices: 
In this study, both esophageal and fundal varices contributes 16%  of  cases of 
total UGI bleed. 
 
Atkinson33  compiled  esophageal varices accounted for an overall 7.3% to 11.1% 
in his  study. 
 
In  OMGE International upper GI Bleeding survey, 1978-86,  Esophageal varices  
was the second most common cause of UGI bleed. 
 
mVan Leerdam et al; AMJ gastro enterol 98:1494, 2003; quoted 7-20% cases of 
UGI bleed were due to varices. 
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6.4.3. Gastric erosion: 
In this study, 10% of cases were due to gastric erosion. 
DM Jensen et al: 200371, mentioned 2-7 % of UGI bleed were due to gastric 
erosion. 
 
Erosive gastritis 7-22% were reported in Johnston SJ, Jones et al, Epidemiology 
and  course of GIH, British Medical Journal 1973. 
 
 The Americal Society for  gastrointestinal Endoscopy National Survey of UGI  
bleed (Gilbert DA, Tedesco FJ, et al), reported 23.4% cases of gastric erosions. 
 
6.4.4. Esophagitis: 
In this study, 8 % of cases were due to Esophagitis 
 
Kc Thromopoulas et al31: European journal gastroenterol Hepatalol 16:2004 
reported 1-13% cases of UGI bleed were due to Esophagitis. 
 
The American Society for gastrointestinal endoscopy national survey (Gilbert et 
al39) reported 6.3 % cases of  esophagitis as a cause for UGI bleed. 
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6.4.5. Carcinoma stomach: 
In this study, 2% of cases of acute UGI bleed were due to Carcinoma Stomach. 
In Jones FA Problems of alimentary bleeding 197037; Gastric cancer accounted for 
2.7% of cases of acute alimentary tract bleeding.  
 
Alum et al described 4.1 cases of gastric carcinoma as a cause of acute GIT bleed. 
Flme et al: Eur JGastroenterol 2005 reported 2-7% cases of  gastric carcinoma. 
 
6.4.6. Varices and Peptic Ulcer: 
In this study, 4%  UGI bleed had both varices and peptic ulcer findings on 
Endoscopy. 
 
In this study, varices and peptic ulcer (4 cases) contributes 20% of total number of 
varices cases(20). 
 
Dagradi AE, Mehler R, Tan et al, AMJ 197035; mentioned other sources of  
bleeding in esophageal varices patients include gastric and duodenal ulcers in upto 
20% of cases. 
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6.4.6. Duodenitis: 
In our study, 4 cases of UGI bleed were found to have Duodenitis on Endoscopy. 
As evident as friable and punctuate erosion of a slightly nodular mucosa, mainly in 
the duodenal bulb, can be a source of blood loss. I In ASGE39 Survey duodenitis 
was observed in  5.8% cases. 
 
6.4.7. Other causes: 
 
Other causes of UGI bleed that occurs in less frequency in this study includes  one 
case of Esophageal ulcer, Hemorrhagic gastritis. 
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CONCLUSION 
The study on endoscopic findings in upper gastro intestinal bleed concludes that   
(1) The peptic ulcer disease was the most common lesion found on endoscopy 
with prevalence of 54%. 
 
(2) Varices contributes second common lesion, next to peptic ulcer disease in 
UGI bleed with prevalence of 16%. 
 
(3) Minor UGI bleed was the commonest presentation. majority of lesions 
(60%) presented with minor UGI bleed 28% lesions presented as moderate 
UGI bleed. Only 8% presented as major UGI bleed.    
 
(4) Varices account for the most common cause for major UGI bleed 
contributing 50%. 
 
(5) Gastric ulcer was commonest lesions accounting for 37 cases (37%) among 
72 cases having single acid peptic lesions on endoscopy. The second most 
common is duodenal ulcer (31%).    
 
(6) Multiple lesions were found in 10% of cases. Peptic ulcer lesions were 
found in 20% of total number of varices cases. 
 
 
 I
 
BIBLIGRAPHY 
1. Marf Feldman, Lawren S, Fried Man, Lawrence J. BrandT Sleisenger and 
Ford Trans gastro intestinal and liver diseases 8th ED. Saunder: 
Philadelphia 2006: 1092 -1096 , 1117 
2. Long streth GF: epidemiology of hospitalization for acute upper gastro 
intestinal hemorrhage; A population based study AMJ gastro enteral 90; 
206, 1995. 
3. Van Lee rdan ME, Ureeburg EM, Rauws, EA, et al; Acute upper GI 
bleeding :  
Did any thing change? Time trend analysis of incidence and outcome of 
acute upper gastro intestinal bleeding between 1993/1994 and 2000 AMJ 
Gastro enterol 98; 1494,2007 
4. Bharucha AE, Gostout CJ, Balm RK; Clinical and endoscopic risk factors 
in the Mallory weiss syndrome AMJ Gastro enteraol 92; 805,1997. 
5. WU, Cypoon, SK, Chen, GH, Chang, CS and yels H. Z. (1999). Interaction 
between helicobacter pylori and NSAID in peptic ulcer bleeding. Scaned J 
Gastro enterol U 33, pp 234 – 237. 
6. Kaufman DW, Kelly JP, Wiholm BE, et al; The risk of acute major upper 
gastro intestinal bleeding among users of aspirin and ibuprofen at various 
levels of alcohol consumption AMJ, Gastro enterol 94; 3189, 1999. 
7. Lane L. Petersen WL, Bleeding peptic ulcer new med 331; 717, 1994 
                          
 II
8. Griffith WJ, Neumann DA, Welsh JD; The visible vessel as an indicator of 
uncontrolled or recurrent gastrointestinal hemorrhage.  
9. Storey DW, Bown SG, Swain Cp, et al; Endoscopic prediction of recurrent 
bleeding in peptic ulcers, Nengl J, Med 305; 915,1981. 
10. 159 – Laine L, Weinstein WM; sub epithelial hemorrhage and erosion of 
human stomach. 1988. 
11. Savidy TJ, Jensen AMJ, Cohen J, et al; Severe upper gastrointestinal 
tumour bleeding  
12. Fockensp, Tytgatgnd, Dieulasoys diseases. Gastroentest endosc clin N am 6 
; 739, 1996. Vascular ectasia; foutch PG; angio dysplasia of the gastro 
intestinal tract. AMJ gastroentrol 88; 807,1993. 
13. Hereditary hemorrahagic telangiectasia:- Longacre AV, Gross CP, Gallitelli 
M, et al, diagnosis and management of gastrointestinal bleeding in patients 
of hereditary hemorrahagic telangiectasia AMJ 98; 59,2003. 
14. Gastric vascular ectasia :- Spahrl, Villenure JP, Dufresne, MP, et al, Gastric 
antral vascular ectasia in cirrhotic patients; Absence of relation with portal 
hypertension gut 44;739,1999. 
15. Fauca, Braunwald, Kasper, Longo, Jameson, Loscal ZO, Harrisons 
principles of internal medicine, 17th ed. Mc Graw; hill 2008, 1855 – 67.. 
16. Rodri guez – Perez F, Grossmann R: Pharmacologic treatment of portal 
hypertension gastroentrol clin. North AM.21; 15,1992. 
17. Myers JD, Taylor WJ: An estimation of portal venous pressure by occlusive 
cathetrisation of a hepatic venule, J clin Invest 30: 662, 1951. 
 III
18. Nevens F, Bustami R, Schley SI, et al: Variceal pressure is a factor 
predicting the risk of a first variceal bleed. A prospective cohort study in 
cirrhotic patients. Hepatology 27: 15, 1998. 
19. Beppu K, Inoquachik, Koyanagi N et  al: Prediction of variceal hemorrhage 
by esophageal endoscopy: Gastrointest endosc 27: 213,1981. 
20. Abraldes JG, Bosch J: Somatostatin and analogs in portal hypertension. 
Hepatology 35: 1305, 2002. 
21. D’ Amico G, Pietosi G, Tarantino I, Pagliaro L, Emergency Sclerotherapy 
versus vasoactive drugs for variceal bleeding in cirrohosis: A Cochrane 
meta analysis. Gastro enterology 124: 1277,2003. 
22. Azoulay D, Castains D, Majnop. et al: Salvage transjugular intrahepatic 
porto systemic shunt for uncontrolled variceal bleeding in patients with 
decompensated cirrohosis J. Hepatology 35. 590, 2001. 
23. De Franchis R, Primignanim: Natural history of portal hypertension in 
patients with cirrhosis predictors and rebleeding  
24. Ben Ariz, Cardin F, MC cormick AP, et al: A predictive model of failure to 
control bleeding during acute variceal hemorrhage. J hepatology 31: 
443,1999. 
25. Imperiale PF, Chalasani: A meta analysis of endoscopic variceal ligation 
for primary prophylaxis of esophageal variceal bleeding hepatology 33: 
802, 2001. 
 IV
26. Bernard B, Grang JD, Khac EN, et al: Antibiotic prophylaxis of prevention 
of bacterial infections in cirrhotic patients with gastro intestinal bleeding: a 
meta analysis hepatology 29: 1655, 1999. 
27. Sarin SK, Lahoti D, Saxena SP, et al: Reference , classification and natural 
history of gastric varices a long term followup study in 568 portal 
hypertension patients hepatology 16: 1643,1992. 
28. Kim T, Shijo H, Kokawa H, et al: Risk factors for hemorrhage from gastric 
fundal varices. Hepatology 25: 307, 1997. 
29. Mvan Leerdam et al: AMJ Gastro enterol 98: 1494,2003. 
30. DM Jensen, et al: Gastro intest endosc 59: AB: 147,2003. 
31. KC, thomopoulos et al: Eurj Gastro enterol. Hepatology 16: 177,2004. 
32. Fdi fiose, et al: EurJ Gastro enterol Hepato 117 – 641,2005. 
33. Alkinson – M. Bleeding from oesophagus in: dykes, pw, Keighleymrb, eds, 
gastro intestinal hemorrhage. Littleton, MA Johnwright PSG, 1981,pp.23-
33. 
34. Lebrecd, Deglenry P, Ruess B, et al – size of varices and risk of gastro 
intestinal bleeding in cirrhosis: gastro enterology 1980; 79; 1139 – 1144. 
35. Dagradi AE, Mehle R, Tan DTD, et al, sources of upper gastro intestinal 
bleeding in patients with liver cirrhosis and large varices AMJ Gastro 
enterol 1970: 54: 458 – 463. 
36. Johnston SJ, Jones PK, Kyle J, et al: Epidemiology and course of GIH in 
North east Scotland DR med 7, 1973- bleeding ascribed to erosive gastritis 
in 7- 227. 
 V
37. In Jones FA, problems of alimentary bleeding- Rend rom gastro enterol 
1970 2: 118 – 132. 
38. Sugawa C, Benishek D, Wahaj, Mallory Weiss syndrome AMJ 1983: 145 : 
30 – 334. 
 
39. Gilbert DA. The national ASGE survey on upper gastrointestinal bleeding: 
III Endoscopy in upper gastrointestinal bleeding. Gastrointest Endosc 1981; 
94 – 102. 
40. Savides TJ, Jensen DM. Therapeutic endoscopy for nonvariceal 
gastrointestinal bleeding. Gastro Clinics of North America 2000; 2: 465 -
87. 
41. Schein M, Gecelter G. APACHE II score in massive upper gastrointestinal 
haemorrhage from peptic ulcer: Prognostic value and potential clinical 
applications. BrJ Surg 1989; 76: 733 – 36. 
42. Zimmerman J, Siguencia J, Tsvnag E, et al. predictors of mortality in 
hospitalized patients with secondary upper gastrointestinal hemorrhage. 
Scand J Gastronterol 1995; 30 : 327 -31. 
43. Rockall TA, Logan RFA, Devlin HB, et al. Risk assessment after acute 
upper gastrointestinal hemorrhage. Gut 1996; 38: 316 -21. 
44. Jensen DM, Machicado GA, Kovacs TOG, et al. Controlled, randomized 
study of heater probe and BICAP for hemostasis of severe ulcer bleeding. 
Gastroenterology 1988; 94 : A208. 
 VI
45. Jensen DM. Management of severe ulcer rebleeding (editorial) N Engl J 
Med 1999; 340 - 799 
46. Forrest JA,Finalyson ND, Sherarman DJ. Endoscopy in gastrointestinal 
bleeding. Lancet 1974; ii: 394 – 97 
47. Silverstein FF, Gibert DA, Tedesco FJ, et al. The national ASGE survey on 
upper gastrointestinal bleeding: II. Clinical prognostic factors. Gastointest 
Endosc 1981; 27 : 80 – 93 
48. Morgan AG, McAdam WAF, Walmsley GL, et al. Clinical findings, early 
endoscopy, and multivariate analysis in patients from the upper 
gastrointestinal tract. BMJ 1977; 2 : 237 – 40. 
49. Shiller KFR, Truelove SC, William DG. Haematemesis and melena, with 
special reference to factors influencing the outcome.BMJ 1970; 2 : 7 -14. 
50. Park KGM, Steel RJC, Mollison J, et al. Prediction of recurrent bleeding 
after endoscopic haemostasis in non – variceal upper gastrointestinal 
haemorrhage. Br J surg 1994; 81: 1465 – 68. 
51. Brullet E, Calvet X, Campo R, et al. Factors predicting failure of 
endoscopic injection therapy in bleeding duodenal ulcer. Gastrointest 
Endosc 1996; 43: 155 – 58. 
52. Jaramillo JL, Galvez C, Carmona C, et al. Predicttors of further hemorrhage 
in bleeding peptic ulcer. Am J Gastroenterol 1994; 89: 2135 – 38. 
53. Lau JYW, Sung JJY, Lam Y, et al. Endoscopic retreatment compared with 
surgery in patients with recurrent bleeding after initial endoscopic control 
of bleeding ulcers. N Engl J Med 1999; 340 : 75 -6. 
 VII
54. Graham DY, Hepps KS, Ramirez FC, et al. Treatment of Helicobacter 
pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J 
Gastroenterol 1993; 28: 939 – 42. 
55. Labenz J, Borsh G, Role of Helicobacter pylori eradication in the 
prevention of peptic ulcer bleeding relapse. Digestion 1994; 55: 19 -23. 
56. Macri G, Milani S, Surrenti E, et al. Eradication of Helicobacter pylori 
reduces the rate of duodenal ulcer rebleeding: a long term follow up study. 
Am J Gasternterol 1998; 93: 925 – 27. 
57. Hay JA, Lyubashevsky E, Elashoff J, et al.. Upper gastrointestinal 
haemorrhage clinical guideline – determining the optimal hospital length of 
stay. Am J Med 1996; 100: 313 – 22. 
58. Rockall TA, Logan RF, Devlin HB, et al. Selection of patients for early 
discharge or outpatient care acute upper gastrointestinal haemorrhage. 
National Audit of Acute Upper Gastrointestinal Haemorrhage. Lancet 
1996; 347: 1138 – 40. 
59. Ghosh S, Watts D, Kinnear M. Management of gastrointestinal 
haemorrhage. Postgrad Med J 2002;78: 4 – 14. 
60. Chak A, Cooper GS, Lloyd LE, et al. Effectiveness of endoscopy in 
patients admitted to be intensive care unit with upper gastrointestinal 
hemorrhage. Gastorintest. Endosc 2001; 53: 6 – 13.  
61. Chung IK, Ham JS, Kim HS, et al. Comparison of hemostatic efficacy of 
the endoscopic hemoclip method with hypertonic saline – epinephrine 
 VIII
injection and a combination of the two for the management of bleeding 
peptic ulcers. Gastorintestinal Endosc 1999; 49: 13 – 18. 
62. Nishiaki M, Tada M, Yanai H, et al. Endoscopic hemostasis for bleeding 
peptic ulcer using hemostatic clip or pure ethanol injection. 
Hepatogastoenterology 2000; 47: 1042 – 44. 
63. Cipolleta L, Bianco MA, Marmo R, et al. Endoclips versus heater probe in 
preventing early recurrent bleeding from peptic ulcer: A prospective and 
randomized trial. Gastrointest Endosc 2001; 53: 147 – 51. 
64. Song SY, Chung JB, Moon YM, et al. Comparison of the hemostatic effect 
of endoscopic injection with fibrin with glue and hypertonic saline – 
ephinephrine  for peptic ulcer bleeding. A prospective randomized trial. 
Endoscopy 1997; 29: 827 – 33. 
65. Kovacs TO. Endoscopic control of gastroduodenal hemorrhage. Ann Rev 
Med 1987; 38: 267 – 7. 
66. Chung SS, Lau JY, Sung JJ, et al. Randomized comparison between 
adrenaline injection alone and adrenaline injection plus heat treatment for 
actively bleeding ulcers. BMJ 1997; 314: 1307 – 11. 
67. Lau JY, Sung JY, Lee KK, et al. . Effect of intravenous omeprazole on 
recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N 
Engl J Med 2000; 343: 310 -16. 
68. Khuroo MS, Yatoo GN, Javid G et al. A comparison of omeprazole and 
placebo for bleeding peptic ulcer. N Engl J Med 1997; 336: 1054 – 8. 
 IX
69. Narayan S, Jensen DM, Randal GM. Gastric bleeding from Dieulafoy’s 
lesion versus peptic ulcer. Gastrointest Endosc 1992; 38: 239. 
70. Abi – Hanna D, Williams SJ, Gillespie PE, Bourke MJ, Endoscopic band 
ligation for non – variceal non – ulcer gastrointestinal hemorrhage. 
Gastrointest Endosc 1998; 48: 510 – 15. 
71. Jensen DM, Kovacs TOG, Machicado GA, et al. Prospective study of the 
stigmata of hemorrhage and endoscopic and medical treatment of bleeding 
Mallory Weiss tears. Gastrointest Endoscopy 1992; 38: 225. 
72. Yamaguchi Y, Yamato T, Katsumi N, et al. Endoscopic hemoclipping for 
upper gastrointestinal bleeding due to Mallory – Weiss syndrome. 
Gastrointest Endosc 2001; 45: 427 – 30. 
73. Savides TJ, Jensen DM, Cohen J, et al. Severs upper gastrointestinal 
tumour bleeding. Endoscopic findings, treatment and outcome. Endoscopy 
1996; 28: 244 – 48. 
74. al – Assi MT, Genta RM, Karttunen TJ, Graham DY. Ulcer site and 
complications: relation to Helicobacter pylori infection and NSAID use. 
Endoscopy. Feb 1996;28(2): 229 – 33. 
75. Boonpongmanee S, Fleischer DE, Pezzullo JC, Collier K, Mayoral W, Al – 
Kawas F, et al. The frequency of peptic ulcer as a cause of upper – GI 
bleeding is exaggerated. Gastrointest Endosc. Jun 2004; 59(7): 788 – 
94.[Medline]. 
 
 
 X
76. Lanas A, Perez – Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S, et al. A 
nationwide study of mortality associated with hospital admission due to 
severe gastrointestinal events and those associated with nonsteroidal anti-
inflammatory drug use. Am J Gastoenterol. Aug 2005; 100(8): 1685 – 93. 
[medline] 
77. Yavorski RT, Wong RK, Maydonovitch C, Battin LS, Furnia A, Amundson 
DE. Analysis of 3,294 cases of upper gastrointestinal bleeding in military 
medical facilities.Am J Gastroenterol. Apr 1995; 90 (4): 568 – 73 
[Medline] 
78. Adler DG, Leighton JA, Davila RE, Hirota WK, Jacobson BC, Queshi WA, 
et al, ASGE guideline: The role of endoscopy in acute non – variceal upper 
– GI hemorrhage. Gastrointest Endosc. Oct 2004; 60 (4): 497 – 504 
[Medline] 
79. Cooper GS, Chak A, Way LE, Hammar PJ, Harper DL, Rosenthal GE. 
Early endoscopy in upper gastrointestinal hemorrhage: associations with 
recurrent bleeding, surgery and length of hospital stay. Gastrointest Endosc. 
Feb 1999; 49 (2) : 145 – 52.[Medline] 
80. Baradarian R, Ramdhaney S, Chapalamadugu R, Skoczylas L, Wang K, 
Rivilis S, et al. Early intensive resuscitation of patients with upper 
gastrointestinal bleeding decreases mortality. Am J Gastroenterol. Apr 
2004; 99(4): 619 – 22.[Medline] 
 
LIST OF ABBREVIATIONS  
 
1) UGI   - Upper Gastro Intestinal 
2) NSAID  - Non Steroidal Anti-Inflammatory   
     Drugs 
 3) H.pylori  - Helicobacter Pylori  
4) NVUGIB  - Non Variceal Upper Gastro Instestinal  
     Bleeding 
5) HVPG  - Hepatic Venous Pressure Gradient 
6) CTP   - Child Turcotte Purg 
7) EVL   - Endo Variceal Ligation 
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     Patients Homodynamic Status, Degree of Blood Loss, and Severity of 
Gastrointestinal Bleedings.        1 
Patients Homodynamic 
Status (Vital Signs) 
 
Blood Loss (%of 
Intravascular 
Volume) 
Severity of Bleed 
 
Shock (resting hypotension) 
Postural (orthostatic 
hypotension and  
               Tachycardia) 
Normal 
20 – 25 
 
10 – 20 
< 10 
Massive 
 
Moderate 
Minor 
  
 
 
Mallory weiss Tear 
 
 
 
 
 
 
 
  
Duodenal ulcer 
 
 
 
 
Gastric ulcer 
 
 
 
  
 
Algorithm for the management of bleeding peptic ulcer due to various etiology 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Algorithm for the management of acute upper gastrointestinal bleeding 
 
 
 
 
 
 
 
  
Endosopic variceal ligation 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A: Proforma – Study on Endoscopic finding in UGI Bleed 
 
 
Department of Internal Medicine, Thanjavur Medical College 
 
1. Name:    2. Age: Yrs:  3. Sex:  M           F 
   
4. IP.No:    5. Ward:   6. unit: 
 
7. Occupation:   8.Monthly Income: 
 
9. Height(in cm) ______  10. Weight (inKg) ______ 
 
12. Hematesis and malena 
 
 
S.No                                History                                Details 
(a) No. of times blood vomited  
(b) Quantity of blood loss each time  
(in milli litre) 
   (1)                 (2)                  (3) 
   (4)                 (5)                  (6) 
(c ) Total quantity of blood loss    (1) < 100ml         (2) 100 to 
1000ml (3) > 1000ml 
(d) H/o Malena  
 
13. Other Symptoms 
 
(a) Abdominal Pain Æ   (B) Heart burn  Æ 
 
(c )Dysphagia Æ    (d) Abdominal lump  Æ 
 
(e) Waterbrash / Vomiting Æ  (f) Dyspepsis  Æ 
 
(g) Jaundice Æ    (h) Any Other bleeding tendency Æ 
 
(i) Syncope Æ    (j) Palpitation  Æ 
 
 
 
 
 
 
 
14. Triggers 
 
(a) Known PUD    (b) Alcoholism             (c) Smoking              (d) NSAID 
 
(e) Steroids    (f) Anti Coagulants 
 
 
15. Past History 
 
(a) HT (b) DM (c ) CAHD (e) H/O Asthma/ COPD 
 
(f) Others (Specify) _______________ 
 
 
16. Clinical examination 
 
(a) Level of consciousness  (b) Dyspnea (c ) Pallor  (d) Icterus  
(e)Pedal edema 
(f) Purpura /Petechiae (g)  Cold clammy extremities (h) Signs of liver cell 
failure (i) Sternal tenderness  (j) RT aspiration to confirm GI bleed   
 
 
17. Vital signs 
 
(a) Pulse rate (supine):     (b) Pulse rate (standing) :    
(c )  BP (supine):    (d) BP (Standing):  
(e) Respiratory rate:   (f) Temp:  
 
18. Examination of system: 
 
(a) Abdomen   : 
 
(b) Respiratory system  : 
 
© Cardiovascular system  : 
 
(d) Central Nervous System : 
 
 
 
 
19. Investigations: 
 
(i) Urine: (a) Albumin (b) Sugar  (c) Bile salt (d) Bile pigment 
 
(ii) CBC  (a) TC    (b) DC   (C ) Hb: 
 
 (d) RBC:     (e) Platelet: 
 
(iii) (a) Bleeding time:    (b ) Clotting time:  (c ) Blood Group 
    
       (d)Blood sugar(R ):       (e) Blood Urea:    (f) Serum Creatinine: 
 
       (g) Serum .Electrolytes: 
 
 
(iv) LFT: (a) SGOT  (b) SGPT (c )Serum. Bilirubin    
   
(d)  Alkaline. Phosphatase  
 
    (e) Serum. Protein  (f) Serum Albumin 
 
(v) Chest X – Ray: 
 
(vi) ECG:  
 
20. Upper GI Endoscopy:  MGE No. :   Date: 
 
(a) Esophagus: 
(b) Stomach: 
(c) Duodenum: 
